Vivos Therapeutics (VVOS) Change in Accured Expenses (2020 - 2026)
Vivos Therapeutics (VVOS) reported Change in Accured Expenses of $125000.0 for Q1 2026, up 127.78% year-over-year from $54878.0 in Q1 2025, and down 95.22% on a QoQ basis from $2.6 million in Q4 2025.
Vivos Therapeutics (VVOS) has 7 years of Change in Accured Expenses data on file, last reported at $125000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 127.78% year-over-year to $125000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 775.2% YoY) and the FY2025 annual result came in at $3.6 million, up 9376.92% from the prior year.
- Change in Accured Expenses slipped to $125000.0 in Q1 2026 per VVOS's latest filing, from $2.6 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.6 million in Q4 2025 and bottomed at -$538000.0 in Q3 2022.
- The 5-year median for Change in Accured Expenses is $33000.0 (2023), against an average of $228764.7.
- The widest annual swing landed in 2024, when Change in Accured Expenses sank 506.06%; it then jumped 113000.0% in 2025.
- Tracing VVOS's Change in Accured Expenses over 5 years: stood at $788000.0 in 2022, then plunged by 106.73% to -$53000.0 in 2023, then advanced by 28.3% to -$38000.0 in 2024, then surged by 6978.95% to $2.6 million in 2025, then sank by 95.22% to $125000.0 in 2026.
- Per Business Quant, the three latest VVOS Change in Accured Expenses figures stand at $125000.0 (Q1 2026), $2.6 million (Q4 2025), and $1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -654.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 703.00 Mn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -512.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -347.10 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 21.07 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 145.10 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -250.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 74.30 Mn |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | 125,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125,000.00 |
| Mar 31, 2026 | 125,000.00 |
| Dec 31, 2025 | 2.61 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Sep 30, 2025 | 358,000.00 |
| Sep 30, 2025 | 358,000.00 |
| Jun 30, 2025 | 248,000.00 |
| Jun 30, 2025 | 248,000.00 |
| Mar 31, 2025 | 398,000.00 |
| Mar 31, 2025 | 398,000.00 |
| Dec 31, 2024 | 254,000.00 |
| Dec 31, 2024 | 254,000.00 |
| Sep 30, 2024 | -87,000.00 |
| Sep 30, 2024 | -87,000.00 |
| Jun 30, 2024 | -338,000.00 |
| Jun 30, 2024 | -338,000.00 |
| Mar 31, 2024 | 132,000.00 |
| Mar 31, 2024 | 132,000.00 |
| Dec 31, 2023 | 328,000.00 |
| Dec 31, 2023 | 328,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | -31,000.00 |
| Mar 31, 2023 | -31,000.00 |
| Dec 31, 2022 | 788,000.00 |
| Dec 31, 2022 | 788,000.00 |
| Sep 30, 2022 | -538,000.00 |
| Sep 30, 2022 | -538,000.00 |
| Jun 30, 2022 | -525,000.00 |
| Jun 30, 2022 | -525,000.00 |
| Mar 31, 2022 | 419,000.00 |
| Mar 31, 2022 | 419,000.00 |
| Dec 31, 2021 | 320,000.00 |
| Dec 31, 2021 | 320,000.00 |
| Sep 30, 2021 | -102,000.00 |
| Sep 30, 2021 | -102,000.00 |
| Jun 30, 2021 | 171,000.00 |
| Jun 30, 2021 | 171,000.00 |
| Mar 31, 2021 | 728,000.00 |
| Mar 31, 2021 | 728,000.00 |
| Dec 31, 2020 | -902,506.00 |
| Dec 31, 2020 | -902,506.00 |
| Sep 30, 2020 | 913,510.00 |
| Sep 30, 2020 | 913,510.00 |
| Jun 30, 2020 | 19,141.00 |
| Jun 30, 2020 | 19,141.00 |
| Mar 31, 2020 | 49,855.00 |
| Mar 31, 2020 | 49,855.00 |